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Objective: To assess the efﬁcacy of tart cherry juice in treating pain and other features of knee osteoar-
thritis (OA).
Methods: 58 non-diabetic patients with Kellgren grade 2e3 OAwere randomized to begin treatment with
cherry juice or placebo. Two 8 oz bottles of tart cherry juice or placebo were consumed daily for 6 weeks
with a 1weekwashout period before switching treatments (crossover design).Western OntarioMcMaster
Osteoarthritis Index (WOMAC) scores and walking times were recorded prior to and after each treatment
period. Additionally, plasmaurate, creatinine andhigh sensitivity C-reactive protein (hsCRP)were recorded
at baseline, after the ﬁrst treatment period and after the second treatment period. Acetaminophen was
allowed as a rescuedrug and self reportedafter each treatment period. Treatment effectwas examinedwith
repeated measures analysis of variance (ANOVA) using an intention-to-treat (ITT) analysis.
Results: There were ﬁve withdrawals during the cherry juice treatment (four adverse events (AEs)) and
seven withdrawals during the placebo treatment (three AEs). WOMAC scores decreased signiﬁcantly
(P < 0.01) after the cherry juice treatment but not after the placebo treatment (P ¼ 0.46); differences
between treatments were not signiﬁcant (P ¼ 0.16). hsCRP declined during the cherry juice treatment vs
placebo (P < 0.01). The decline in hsCRP was associated with WOMAC improvement (P < 0.01). Walking
time, acetaminophen use, plasma urate and creatinine were unaffected by treatments.
Conclusions: Tart cherry juice provided symptom relief for patients with mild to moderate knee OA, but
this effect was not signiﬁcantly greater than placebo. Tart cherry juice lowered hsCRP levels and this
effect was associated with improved WOMAC scores.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Nonoperative treatments for patientswithmild tomoderate knee
osteoarthritis (OA) include nonsteroidal anti-inﬂammatory medica-
tions, intra-articular injections (corticosteroids, hyaluronic acid) or
non-pharmacological treatments such as physical therapy, exercise,
lifestyle alterations, and nutritional supplementation1. While
nonsteroidal anti-inﬂammatory drugs (NSAIDs) are commonly usedto: M.P. McHugh, Nicholas
ox Hill Hospital, 100 E 77 ST,
.edu (H.R. Schumacher),
mita.Gupta@uphs.upenn.edu
ella), rosakim330@gmail.com
s Research Society International. Pnonoperative treatment for mild to moderate knee OA, alternative
treatments are increasingly sought due to the cardiovascular and
gastrointestinal side effects of NSAIDs1. Dietary supplements such as
glucosamine, chondroitin sulfate, and methylsulfonylmethane have
been examined in the treatment of knee OA but with equivocal efﬁ-
cacy2e5.
Dietary interventions for knee OA have focused on weight loss6
since body mass index (BMI) is a risk factor for disease progression.
Less attention has been given to the role of natural food products in
the treatment of knee OA. Consumption of cherries or cherry juice
has traditional reputation for alleviating pain in arthritis and gout7.
While supporting clinical trials are lacking, a growing body of
literature indicates that cherries can have signiﬁcant anti-
inﬂammatory, antioxidant and pain-mediating effects. Studies
have identiﬁed a range of phenolic compounds in cherries that haveublished by Elsevier Ltd. All rights reserved.
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demonstrated in animal models of cancer12, and arthritis13 along
with pain mediating effects14. Consumption of tart cherry juice has
been shown to reduce pain15,16, muscle damage15,17, inﬂammation17
and oxidative stress17 after strenuous exercise. Additionally, anti-
oxidant and anti-inﬂammatory effects from eating cherries or
drinking cherry juice have been demonstrated in healthy humans
in non-exercisemodels18e20. Kelley et al.19 reported a 25% reduction
in high sensitivity C-reactive protein (hsCRP) when healthy adults
ate 280 g of sweet cherries daily for 28 days.
OA progression is associated with inﬂammation and oxidative
stress21,22. Elevated baseline hsCRP in patients with knee OA was
associated with greater subsequent cartilage loss and a poorer
symptomatic response to treatment22. Similarly, patients with knee
OA had increased oxidative stress and decreased total antioxidant
capacity21. Prolidase activity, a marker of collagen resynthesis, was
inversely correlated with markers of oxidative stress and positively
correlated with antioxidant capacity.
Since consumption of cherries or cherry juice decreased CRP17,19,
and oxidative stress17,20 and increased total antioxidant capacity17,
it was hypothesized that such effects might provide symptom relief
in patients with knee OA. The primary purpose of this study was to
test the ability of a tart cherry juice blend to provide symptom relief
in knee OA. It was hypothesized that consumption of cherry juice
would show a measurable difference on the Western Ontario
McMaster Osteoarthritis Index (WOMAC) scale evaluating pain,
stiffness and function, the amount of non-prescription pain medi-
cation taken, the score on a timed walking test23, and in hsCRP as a
measure of low grade inﬂammation in OA24. Because of previous
reports suggesting beneﬁt from cherry consumption on gout pain7
and serum uric acid (UA)18, this was also examined.
Methods
Participants
Subjects were identiﬁed during June 2007eJune 2010 by phy-
sicians in the Rheumatology or Primary Care Clinics at the
Department of Veterans Affairs Medical Center in Philadelphia, PA
based on presence of clinical OA and evaluated, and treated in the
Rheumatology Clinic. The study was approved by the institutional
review board, with all patients providing written informed consent
before participating and the study was performed in compliance
with the Helsinki declaration.
Inclusion criteria were capacity to give informed consent, age
over 18 years, andmild tomoderate OA of the knee that met clinical
ACR criteria25 (knee pain plus at least three of the following six):
age >50 years, stiffness <30 min, crepitus, bony tenderness, bony
enlargement, and no palpable warmth. Kellgren grade had to be 2e
3 on a standing knee X-ray within the previous 24 months, and a
VAS pain score of 4e9 at the screening visit.
Exclusion criteria were rheumatoid arthritis or other systemic in-
ﬂammatory condition, chronic pain syndrome (ﬁbromyalgia), corti-
costeroid medication in last 2 months (intra-articular or oral), intra-
articular injections of hyaluronic acid in the last 9 months, preg-
nancy, diabetes, inability to discontinue prescription medication for
arthritis, unstable medical conditions that would likely prevent the
subject fromcompleting thestudy, or foodallergiese cherries, apples.
Trial agents
This study used a cherry juice blend that is regulated by the food
and drug agency (FDA) as a food, not a drug. The blend and placebo
were prepared by Cherrypharm Inc., Geneva, NY. The cherry juice
was prepared by mixing freshly prepared tart cherry juice withcommercially available apple juice (>90% cherry juice). Frozen tart
cultivar Montmorency cherries were used to prepare the cherry
juice following standard procedures. The blended juice was
pasteurized by heating to 85C, hot packed into 8 oz. polyethylene
(PET) bottles with a 3min hold time to achieve commercial sterility,
and then force cooled in a water tunnel. One 8 oz bottle of the juice
provided at least 450 mg phenolic compounds, expressed as gallic
acid equivalents by themethod of Singleton and Rossi26 and at least
30 mg anthocyanins, calculated as cyanidin-3-glucoside equiva-
lents by the pH differential method described by Giusti et al.27. Each
bottle contained the equivalent of 50 cherries.
The placebowasmatched for color, sweetness and cherry ﬂavor. It
waspreparedbymixingunsweetenedblack cherryKool-aid soft drink
mix (Kraft North America, Ryebrook, New York, USA; ingredients lis-
ted: citricacid, salt, calciumphosphate, red40, artiﬁcialﬂavor, ascorbic
acid, blue 1) with water in the proportion recommended by the
manufacturer (about 2 g/l). There was no true cherry in the placebo.
Sugar was added to match the concentration of soluble solids in the
cherry juice blend to a ﬁnal concentration of 13Brix (total percentage
soluble solids by weight). One degree of Brix equals 1 g of sucrose in
100 gof solution. A clouding agent (whichwas listed on the ingredient
statementasﬂavor)wasadded to increase the turbidityof theKool-aid
in order to look similar to juice. The ﬂavored beverage was then
pasteurized and bottled following the same procedure used for the
juice. Both the placebo and juice blend contained 31 g of sugar per
serving.
Subjects were randomized by a computer program developed
by the research pharmacy. Investigators and subjects were blinded
to group assignments.
In this crossover design subjects began taking cherry juice or
placebo at visit two (visit one screening/baseline visit) after a
washout period of at least 1 week from any prescription pain
medications. After 6 weeks of using either cherry juice or placebo
they began taking the alternative treatment at visit four, after a
washout period of not less than 1 week between the treatment/
placebo legs of the study.
Acetaminophen was allowed as a rescue medication (500 mg
tablets) and subjects recorded their intake in a diary and took no
acetaminophen for 12 h before each visit. NSAIDs or other anal-
gesics were not allowed.
Subjects were shipped a 6-week supply of juice or placebo in
8 ounce bottles at visit two and visit four, and instructed to drink
one bottle each in the morning and evening. All bottles were
shipped back at visit three and visit ﬁve. These were counted to
determine compliance. Rationale for the dosage is based on pre-
vious studies on muscle damage and oxidative stress15,17,20.
Outcome measures
WOMAC (VA 3.1) score was the primary outcome measure
including pain, stiffness and function subscale (scales from 0 to 100
for each subscale). Secondary outcome measures were plasma
hsCRP, UA and creatinine, time to walk 10 m23 and acetaminophen
use. WOMAC scores and timed walking tests were recorded at
baseline, after the ﬁrst 6-week treatment, after the washout period
(prior to the second treatment) and after the second treatment.
Blood samples were drawn at baseline, after the ﬁrst treatment and
after the second treatment. Analyses were performed by random
access immunoassay analyzer using standard enzyme based creat-
inine and UA tests, and infrared particle immunoassay for hsCRP.
Safety monitoring
All adverse events (AEs) were recorded as mild, moderate or
severe and the perceived relationship to the treatment noted. The
Fig. 1. Breakdown of randomization of treatments showing treatment order, number
of patients completing each period of the study, withdrawals and AEs. One patient who
sustained a back injury in the ﬁrst treatment period (cherry juice) was not included in
analysis of WOMAC scores because the back injury necessitated taking NSAIDs. Any
improvement in WOMAC score was confounded by the potential beneﬁt of the NSAID
regardless of any effect of cherry juice.
Table I
Baseline characteristics of the patients
Age (year) 56.7  11.3
Gender 44 men, 14 women
Race 39 African American, 19 White
BMI 31.8  6.2
BMI classiﬁcation 7 normal, 17 overweight, 34 obese
Baseline WOMAC 48.2  19.9
NSAID Use (prior to enrollment) 10 yes, 48 no
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Institute’s (NCI’s) Common Toxicity Criterion for AEs version 3
(CTCAEv3)28. Where a CTCAE criterion did not exist we used the
following grade: 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe, 4 ¼ life
threatening or disabling, and 5 ¼ fatal. The relationship of AEs to
the cherry juice blend was assessed by means of the question: “Is
there a reasonable possibility that the event may have been caused
by the study supplement?” Answer Yes or No.
Statistics
For statistical analyses of WOMAC scores within subjects factors
(repeated measures) were Treatment (cherry juice vs placebo) and
Time (pre treatment vs post treatment), and the between subjects
factor was Treatment Order (cherry juice or placebo in ﬁrst period).
Total WOMAC scores, and each subscale were analyzed with
Treatment  Time  Treatment Order mixed-model analysis of
variance (ANOVA). If a signiﬁcant three-way interaction occurred
the Treatment  Time effects were reported for each treatment
period separately (patients starting with cherry juice then pro-
ceeding to placebo vs patients starting with placebo then pro-
ceeding to cherry juice). Effect of Time (pre treatment vs post
treatment) within each treatment period (cherry juice or placebo)
was assessed using paired t-tests with Bonferroni corrections for
planned pairwise comparisons (P value multiplied by two).
WOMAC scores were analyzed with an intention to treat approach
(ITT). If a patient dropped out during the initial treatment period
and a post treatment WOMAC was not obtained (n ¼ 7) the pre
treatment WOMAC was entered as the post treatment score. Since
these patients did not receive a treatment in the second treatment
period no attempt was made to impute missing data. For patients
dropping out during the second treatment period (n ¼ 3) pre
treatment WOMAC scores were entered as the post treatment
score.
Based on the responsiveness of the WOMAC score to acet-
aminophen, celecoxib and placebo in subjects with knee and hip
OA29, and the excellent testeretest reliability of the WOMAC
score30, it was estimated that a 5.5 point difference in the change in
WOMAC scores between cherry juice and placebo could be detec-
ted at P < 0.05 with 80% power using a sample of 50 subjects.
Allowing for a 20% dropout rate (which is higher than expected) the
detectable effect size was estimated to be 6.5 points. In a previous
study the difference in the change inWOMAC score was 6e8 points
between placebo and celecoxib, 2e3 points between placebo and
acetaminophen, and 3e5 points between celecoxib and
acetaminophen29.
As a secondary analysis patients were classiﬁed as having a
positive treatment response if the WOMAC pain or function scores
improved by at least 50% and at least 20 points, or if both scores
improved by at least 20% and by at least 10 points. Treatment dif-
ferences were assessed with Fisher exact tests. Effects of gender,
race and BMI on treatment effects were also assessed using mixed-
model ANOVA.
Since blood samples were only taken on three occasions
(baseline, post ﬁrst treatment, and post second treatment) these
variables were analyzed using Time by Treatment Order (cherry
juice ﬁrst vs placebo ﬁrst) mixed-model ANOVA. Effect of change in
hsCRP on WOMAC scores in each treatment group was assessed by
independent t-tests comparing WOMAC scores between patients
greater than and less than the median change for the respective
treatment.
Compliance was compared between placebo and cherry juice
treatments using Chi-Square analysis or Fisher’s exact test,
where appropriate, to compare dropout rates and paired t-tests
to compare consumption of juice and placebo bottles based onthe number of empty bottles returned after each treatment
period.Results
Compliance
Fifty-nine patients were enrolled with 27 randomized to begin
with the cherry juice treatment and 32 to begin with the placebo
treatment. One patient scheduled to begin with the placebo treat-
ment withdrew before the study began, as he was not prepared to
withdraw from medication for OA. Thus data on 58 patients are
reported (44 men, 14 women; 57  11 yo; 98.5  19.0 kg;
177  8 cm; Table I). Forty-six patients completed both treatments
(Fig. 1). Of the 12 patients who did not complete both treatments
seven dropped out during the ﬁrst treatment period (three cherry
juice, four placebo), two dropped out between the ﬁrst and second
treatments (both after cherry juice treatment) and three dropped
out during the second treatment (all placebo). For ITT analysis 49
patients were included in the Treatment by Time analysis. For an-
alyses of the main effect of time 53 patients were included for the
cherry juice treatment and 53 were included for the placebo
treatment.
Compliance with allocated treatment was similar for the two
treatments with respect to the number of empty bottles returned
after each treatment (92  16% cherry juice vs 89  17% placebo;
P ¼ 0.27).
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Total WOMAC scores improved signiﬁcantly during the cherry
juice treatment (P ¼ 0.002) and did not change during the placebo
treatment (P ¼ 0.46). The change in WOMAC scores was not
signiﬁcantly different between treatments (P ¼ 0.16, Table II).
Treatment order (cherry juice or placebo ﬁrst) did not affect
changes in total WOMAC scores, or pain and function scores, but
did affect stiffness scores (Table II). During the cherry juice treat-
ment there were signiﬁcant improvements in pain (P ¼ 0.042), and
function (P < 0.001) with no change during the placebo treatment
(P ¼ 0.99, P ¼ 0.81, respectively; Table II). For patients beginning
with the cherry juice treatment improvements in stiffness scores
were greater during the cherry juice treatment vs the placebo
(P¼ 0.048) but this was not the case for patients beginningwith the
placebo treatment (P ¼ 0.29). A sensitivity (per protocol) analysis
including the 46 patients who completed both treatments similar
results as the ITT analysis (Table II).Table II
WOMAC results
Cherry juice
n ¼ 53
Placebo
n ¼ 53
Difference
n ¼ 49
P value
difference
WOMAC
score
Pre treatment 46.1  23.2 45.8  23.5 1.7  17.1 P ¼ 0.98
Post treatment 39.2  25.1 43.0  27.0 2.7  17.6 P ¼ 0.58
Difference 6.9  13.7 2.8  16.9 4.4  23.6 P ¼ 0.16*
95% CI
difference
3.1e10.7 1.8 to 7.5 2.4 to 11.2
P value ITT P ¼ 0.002 P ¼ 0.46 P ¼ 0.16*
P value per
protocol
P ¼ 0.002 P ¼ 0.52 P ¼ 0.15*
Pain
score
Pre treatment 42.1  22.9 41.5  24.4 0.9  18.0 P ¼ 0.99
Post treatment 36.3  27 40.0  26.6 3.6  20.5 P ¼ 0.46
Difference 5.8  17.7 1.5  17.4 4.5  27.3 P ¼ 0.24*
95% CI
difference
0.9e10.7 2.9 to 6.8 3.7 to 11.7
P value ITT P ¼ 0.042 P ¼ 0.99 P ¼ 0.24*
P value per
protocol
P ¼ 0.07 P ¼ 0.99 P ¼ 0.21*
Stiffness
score
Cherry juice in ﬁrst treatment period
n ¼ 26 n ¼ 22 n ¼ 22
Pre Treatment 51.1  29.3 39.5  34.3 13.4  27.8 P ¼ 0.07
Post Treatment 39.1  30.1 42.4  32.8 3.6  16.3 P ¼ 0.64
Difference 12.0  26.3 2.9  20.0 16.9  37.9 P ¼ 0.048*
95% CI
Difference
1.4e22.6 11.7 to 6.0 0.1e33.7
P Value ITT P ¼ 0.06 P ¼ 0.99 P ¼ 0.048*
P Value per
protocol
P ¼ 0.08 P ¼ 0.99 P ¼ 0.06*
Cherry juice in second treatment period
n ¼ 27 n ¼ 31 n ¼ 27
Pre treatment 48.3  25.8 55.1  19.8 6.1  21.2 P ¼ 0.30
Post treatment 44.0  28.5 47.0  26.8 1.5  19.7 P ¼ 0.99
Difference 4.3  19.1 8.1  18.8 4.6  22.1 P ¼ 0.29*
95% CI
difference
3.3 to 11.8 1.2e15.0 13.3 to 2.2
P value ITT P ¼ 0.52 P ¼ 0.046 P ¼ 0.29*
P value per
protocol
P ¼ 0.52 P ¼ 0.06 P ¼ 0.29*
Function
Score
Pre treatment 46.9  23.7 46.7  24.0 1.8  17.9 P ¼ 0.96
Post treatment 39.1  25.9 44.7  27.2 4.4  18.9 P ¼ 0.22
Difference 7.8  13.7 2.0  17.2 6.2  24.9 P ¼ 0.13*
95% CI
difference
4.0e11.6 1.9 to 7.9 2.0 to 12.3
P value ITT P ¼ 0.0002 P ¼ 0.81 P ¼ 0.13*
P value per
protocol
P ¼ 0.0002 P ¼ 0.48 P ¼ 0.16*
Mean  SD; *Signiﬁcance of Time by Treatment interaction; other P values adjusted
for planned pairwise comparisons (P values multiplied by 2). Stiffness scores
differentiated by treatment order because of signiﬁcant three-way interaction
(Time  Treatment  Treatment Order P ¼ 0.017 for ITT analysis and P ¼ 0.016 for
per protocol analysis). The three-way interaction was not signiﬁcant for total
WOMAC scores (P ¼ 0.2), Pain scores (P ¼ 0.14) and Function scores (P ¼ 0.27).A positive treatment response occurred in 21 of 53 patients
during the cherry juice treatment vs 11 of 53 patients during the
placebo treatment (P ¼ 0.06).
WOMAC scores prior to the second treatment period
(43.8  25.7) were not different from baseline scores (48.2  19.9;
P ¼ 0.06) or different from scores at the end of the ﬁrst treatment
period (42.8  24.7; P ¼ 0.33). For patients who started with the
cherry juice treatment WOMAC scores prior to the placebo treat-
ment (41.4  30.5) tended to be lower than baseline values
(48.0  24.8; P ¼ 0.065) and not different from values at the end of
the cherry juice treatment (39.3  26.9; P¼ 0.47). For patients who
started with the placebo treatment WOMAC scores prior to the
cherry juice treatment (44.3  23.2) were not different from
baseline values (46.6  15.0; P ¼ 0.49) or values at the end of the
placebo treatment (41.0  24.6; P ¼ 0.15).
Treatment effects on WOMAC scores were unaffected by race
(P ¼ 0.5) and BMI (P ¼ 0.62), with a trend for an effect of gender
(P ¼ 0.09); WOMAC improvement during the cherry juice treat-
ment was not different between genders (0.99) but during the
placebo treatment WOMAC scores improved somewhat in men
(n ¼ 40) and declined somewhat in women (n ¼ 13; gender effect
P ¼ 0.09).
Other outcome measures
Acetaminophen use was not different between treatments in
the 41 patients who provided records of use in both treatment
periods. During the cherry juice treatment average use of acet-
aminophen was 85  77 tablets compared with 83  74 tablets
during the placebo treatment (P ¼ 0.83). Timed walking perfor-
mance was documented for 46 patients prior to and after both
treatments. Walking performance was unaffected by treatment
(Cherry juice treatment Pre 11.0  3.7 s, Post 10.6  2.8 s; Placebo
treatment Pre 11.3  4.7 s, Post 11.2  4.2 s; Time effect P ¼ 0.13,
Time by Treatment P ¼ 0.43).
Serum markers
Serum samples were obtained from all 58 patients at baseline,
from 52 patients after the initial treatment period and from 44
patients after the second treatment period. Urate and creatinine
levels were unaffected by the treatments (Time by Treatment Or-
der: UA P ¼ 0.5, creatinine P ¼ 0.84; Table III). At baseline 13 of 58
patients had hyperuricemia (>6.8 mg/dl). This did not affect
changes in UA during placebo vs cherry juice treatment
(Time  Treatment Order  Hyperuricemia P ¼ 0.78).
Serum hsCRP levels were signiﬁcantly affected by the treatment
(Time by Treatment Order P ¼ 0.006, Table III). For patients who
began with the cherry juice treatment hsCRP declined from base-
line to the end of the treatment and then increased from end of theTable III
Serum markers at baseline, after the ﬁrst treatment period and after the second
treatment period. Mean  SD
Pre ﬁrst
treatment
Post ﬁrst
treatment
Post second
treatment
hsCRP (mg/L) Cherry juice ﬁrst 2.38  1.83 1.98  1.73 3.49  4.00
Placebo ﬁrst 2.99  2.39 4.21  2.98 3.17  2.55
UA (mg/dl) Cherry juice ﬁrst 6.08  1.51 5.85  1.13 6.02  1.25
Placebo ﬁrst 6.10  1.41 6.31  1.99 6.32  2.05
Creatinine
(mg/dl)
Cherry juice ﬁrst 1.01  0.218 1.02  0.202 1.03  0.202
Placebo ﬁrst 1.14  0.422 1.12  0.424 1.13  0.368
Time  Treatment Order: hsCRP P ¼ 0.006; UA P ¼ 0.50; Creatinine P ¼ 0.84.
Decreased hsCRP during cherry juice treatment (P¼ 0.043); increased hsCRP during
placebo treatment (P ¼ 0.004).
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opposite was true for patients who began with the placebo treat-
ment; hsCRP levels increased from baseline to the end of the pla-
cebo treatment and then declined from the end of the placebo
treatment to the end of the cherry juice treatment (Table III).
Overall hsCRP decreased by 23% during the cherry juice treatment
(P ¼ 0.043) and increased by 51% during the placebo treatment
(P ¼ 0.004).
Patients in whom hsCRP decreased more than the median value
during the cherry juice treatment (>10% decrease, n ¼ 23) showed
signiﬁcantly greater improvements in total WOMAC scores
(P ¼ 0.01, Fig. 2) than patients whose hsCRP did not decrease more
than the median value (10% decrease, n ¼ 21) (Fig. 2).
Ten of 58 pts were on NSAIDs at the time of the ﬁrst blood draw.
Baseline hsCRP levels were 3.1  3.0 mg/L for 10 NSAID users and
3.2  3.1 mg/L for the 45 non-users and the three NSAID users who
had withdrawn a week prior (P ¼ 0.91). NSAID use did not affect
changes in hsCRP over time between the cherry juice and placebo
treatments (Time  Treatment Order  NSAID use P ¼ 0.17).
Changes in WOMAC scores were not different between patients
with above vs belowmedian increases in hsCRP during the placebo
treatment (P ¼ 0.75).
Effectiveness of blinding
At the end of the cherry juice treatment 57% of patients thought
that they had been on the cherry juice. At the end of the placebo
treatment 63% of patients thought that they had been on the pla-
cebo. Thus adequate blinding was achieved. Changes in WOMAC
scores between treatments were unaffected by whether the pa-
tients correctly determined if they were on placebo or cherry juice
(Time  Treatment  correct vs incorrect determination P ¼ 0.26).
Safety
Of the 12 patients who did not successfully complete both
treatments, seven experienced AEs (four during the cherry juice
treatment, three during the placebo treatment). The AEs during the
cherry juice treatment were (1) a skin reaction due to possible al-
lergy to cherries (withdrew during ﬁrst treatment period), (2)
gastrointestinal symptoms (withdrew after completing cherry juice
treatment but was not compliant with taking juice; this was ﬁrstFig. 2. Effect of decrease in hsCRP during cherry juice treatment on improvement in
WOMAC scores. Black bars are patients that had >10% decrease in hsCRP. White bars
are patients with 10% decrease in hsCRP. *Greater improvement in patients with
decreased hsCRP vs patients with no change in hsCRP tested by independent t-test
(WOMAC P ¼ 0.01; Function P ¼ 0.004; Pain P ¼ 0.23; Stiffness P ¼ 0.82).
Mean  standard error (SE) for % improvement in WOMAC scores displayed.treatment period), (3) low back injury during exertion which
necessitated taking an NSAID (withdrew after cherry juice treat-
ment (ﬁrst treatment) and WOMAC data not included since NSAID
use confounded symptom change) and (4) elevated blood glucose
at the end of the cherry juice treatment and withdrawn from study
before placebo treatment. The AEs during the placebo treatment
were (1) patient withdrew due to increased symptoms and sought
treatment for suspected meniscal tear (placebo was the second
treatment), (2) elevated blood glucose and blurry vision (placebo
was ﬁrst treatment and patient withdrew from study), (3)
increased symptoms necessitating withdrawal after placebo treat-
ment (ﬁrst treatment).
Of the remaining ﬁve patients who did not complete both pe-
riods of the study one withdrew during the cherry juice treatment
(ﬁrst treatment) because she did not like the taste of the juice and
four were lost to follow-up (three during the placebo treatment and
one during the cherry juice treatment; three of these four patients
were lost to follow-up during ﬁrst treatment period).
Discussion
These data provided the ﬁrst objective evidence that the cherry
juice as studied here can have beneﬁcial effects for patients with
OA. WOMAC scores improved during the cherry juice treatment
with no signiﬁcant improvement during the placebo treatment.
However, the improvement during the cherry juice treatment (15%)
was not signiﬁcantly different from the change during the placebo
treatment (6%), thus, clear efﬁcacy was not demonstrated. The
cherry juice treatment resulted in a reduction in hsCRP (23%) that
contrasted with a 51% increase in hsCRP during the placebo treat-
ment. The reduction in hsCRP during the cherry juice treatment
was associated with improvements in WOMAC scores (Fig. 2)
indicating that symptom improvement may have been due to an
anti-inﬂammatory effect of the cherry juice. However, it is unclear
why the elevation in hsCRP with the placebo treatment was not
associated with an increase in symptoms as measured by WOMAC
scores. The cherry juice effect is consistent with studies on healthy
individuals showing anti-inﬂammatory effects of cherries17,19 and
may prove beneﬁcial in other clinical conditions.
The increase in hsCRP during the placebo treatment may be
attributable to the sucrose content of the drink (31 g per 8 ﬂ oz
bottle). Aerberli et al.31 showed that consumption of sugare
sweetened beverages elevated hsCRP. Consumption of beverages
containing 80 g sucrose per day, for 3 weeks, resulted in a 105%
increase in hsCRP. In the present study patients consumed 62 g
sucrose per day for 6 weeks during the placebo treatment and
hsCRP increased by 51%. Aeberli et al.31 studied healthy young men
with normal baseline hsCRP values (0.21 mg/L) while patients with
OA in the present study had elevated baseline hsCRP (3.2 mg/L). Of
note, the sucrose content of the cherry juice was the same as the
placebo. Presumably the cherries counteracted the negative effect
of sucrose. Cherry juice with a lower sucrose level may prove even
more beneﬁcial in reducing hsCRP.
The baseline hsCRP values in the present study (3.2  3.1 mg/L)
are comparable to values reported for a larger sample of patients
(n ¼ 755) with knee or hip OA (3.4  4.7 mg/L)24. Importantly,
systemic hsCRP levels were associated with increased synovial
inﬂammation in the affected joints24. Future research is needed to
determine if synovial inﬂammation is reduced in parallel with
reduced hsCRP levels in patients with knee OA consuming cherry
juice.
Since an effect of cherries on gout ﬂares and UA levels has been
suggested7,32,33 it is of interest that we found no effect on UA.
Baseline UA values were within normal limits and did not change
with 6-week consumption of tart cherry juice. Fructose-rich
H.R. Schumacher et al. / Osteoarthritis and Cartilage 21 (2013) 1035e10411040beverages have been reported to actually increase UA in some tri-
als34,35. More studies will be needed to determine if cherry juice
suppresses inﬂammation in patients with gout and if it thus can
decrease ﬂares.
There are limitations to this study. As a small short study it
should be considered as hypothesis generating and additional trials
are merited. Patients with diabetes were not studied and are not
ideal candidates for this treatment because of the sugar content in
the juice.
The WOMAC scores were more variable than expected in terms
of absolute values and responsiveness to treatment when
compared to the studies on which the sample size estimates were
based29,30. The study was powered to detect a difference in
WOMAC improvement between treatments of 5.5. A difference of
4.4 was detected. Thus given the higher than expected variability
and the smaller response difference the power to detect a treat-
ment effect greater than placebo was less than expected.
The potential for multiplicity of inﬂuences contributing to the
variability in treatment outcomes is an inherent problem in studies
on OA. In the present study the use of a crossover design and
including treatment order as a factor in the ANOVA served to
minimize multiplicity of inﬂuences on WOMAC scores. Addition-
ally, effects of BMI and race were insigniﬁcant. A trend for an effect
of gender (P¼ 0.09) was not expounded on since therewere only 13
women in the study.
Typically the WOMAC pain subscale is the most responsive
subscale to treatment, but that was not the case here. The function
subscale showed a larger improvement. The effect of reduced
hsCRP on WOMAC scores during the cherry juice treatment was
apparent for the function and stiffness subscales, but not for the
pain subscale. It is unclear why the pain subscale was less
responsive in this study.
The lack of a signiﬁcant placebo effect is inconsistent with most
randomized clinical trials in OA. This may be due to patient ex-
pectations in a trial testing a food vs a drug. For example, studies
examining the beneﬁts of food supplements have also shown no
signiﬁcant placebo effect on WOMAC scores36e38.
Conclusion
In conclusion, WOMAC scores improved signiﬁcantly when pa-
tients were taking tart cherry juice but this effect was not signiﬁ-
cantly better than placebo. Additionally, patients had signiﬁcantly
decreased hsCRP when taking cherry juice compared to placebo.
The decline in hsCRP when taking cherry juice was associated with
improved WOMAC scores. Both cherry juice and placebo were
generally well tolerated.
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